Missouri Bill Would Add Psychedelics to ‘Right to Try’ Law

A Missouri lawmaker has proposed expanding the state’s Right to Try law to include psychedelic substances such as psilocybin, MDMA, LSD, mescaline, ibogaine, and DMT.

Full story after the jump.

Missouri Republican state Rep. Michael Davis last week introduced a measure to expand the state’s Right to Try statute to include Schedule I investigational drugs, including psilocybin, MDMA, LSD, mescaline, ibogaine, and DMT. The drugs would only be available after all other treatment options have been exhausted.

The Right to Try Law, enacted in the state in 2014, allows patients with terminal illnesses to access “investigational drugs and devices” that are not approved by the Food and Drug Administration but stops short of allowing Schedule I drugs.

In a statement released by drug policy reform political action committee Crossing Paths PAC, Davis said, “Many psychedelic drugs have decades of clinical research supporting their efficacy and safety profiles, yet the FDA has been slow to act to reschedule these drugs.”

“My proposal protects the liberty interests of Missourians who believe these drugs offer valuable options in the treatment of numerous conditions, and, importantly, aligns Missouri law with federal law with respect to investigational drug access.” – Davis, in a statement, via Crossing Paths

In 2018, Republican state Rep. Dr. Jim Neely introduced legislation that would have expanded the Right to Try law to include medical cannabis access without license caps, Crossing Paths noted. That bill was approved by the state House but rejected by the Senate.

The measure would also reduce criminal penalties for non-patients possessing the drugs listed in the legislation.

The measure carries no co-sponsors and has not yet been moved to a committee.

Get daily cannabis business news updates. Subscribe

Have an additional perspective to share? Send us a message to let us know, and if your comment is chosen by our editors it could be featured here.


Latest Cannabis News

View all news Get email updates

Featured Business Profiles

Create a profile View all categories

From Our Partners